Anne Carpenter: An Open Source Proponent On What Pharma Does And Doesn’t Owe Academia
Executive Summary
Anne Carpenter, one of In Vivo’s 2021 Rising Leaders, talks about the growth of open source technology, putting data into action and why pharma deserves to be rewarded for evolving academic findings into marketable products for patients.
You may also be interested in...
Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested
The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.
Califf Clears First Senate Hurdle, But FDA Decision On Abortion Pill May Complicate Final Confirmation
Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.
Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation
Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.